Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIC - WACC | 56.0% | 97.1% | (139.8%) | 104.8% | 107.8% | 86.3% | 56.1% | 44.5% | 20.7% | 14.1% | 63.6% | 89.3% | 68.7% | 18.9% | 16.7% | 12.2% | 10.4% | 6.2% | 6.0% | 7.4% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month ROIC - WACC is 14.2%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual ROIC - WACC for Gilead Sciences, Inc. have been 9.0% over the past three years, and 8.4% over the past five years.
As of today, Gilead Sciences, Inc.'s ROIC - WACC is 14.2%, which is higher than industry median of 8.9%. It indicates that Gilead Sciences, Inc.'s ROIC - WACC is Good.